1 Min Read
Jan 10 (Reuters) - Nektar Therapeutics
* Nektar Therapeutics says as of December 31, 2016, company estimates had cash and investments in marketable securities of approximately $389 million Source: (bit.ly/2jfPIe1) Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.